CIK 0001175151 · Non-accelerated filer<br>Smaller reporting company
Cytosorbents Corp
Sign in to watch- Ticker
- CTSO
- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 980373793
- Phone
- 973-329-8885
- Business address
- 305 COLLEGE ROAD EAST, PRINCETON, NJ, 08540
- Former names
- MedaSorb Technologies CORP, GILDER ENTERPRISES INC
- Open-market buys, last 90 days
- $120,435
- in 4 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$120,435. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-15 | Chan Phillip P. Chief Executive Officer | Purchase | +3,774 | $6.00 | $23K | 100,996 |
| 2026-09-04 | Chan Phillip P. Chief Executive Officer | Purchase | +200,000 | $0.35 | $70K | 1,944,432 |
| 2026-06-15 | Chan Phillip P. Chief Executive Officer | Purchase | +10,333 | $0.43 | $4K | 1,744,432 |
| 2026-06-12 | Chan Phillip P. Chief Executive Officer | Purchase | +251,136 | $0.40 | $100K | 1,734,099 |
| 2025-11-18 | Chan Phillip P. Chief Executive Officer | Grant or award | +100,000 | $0.64 | $64K | 1,482,963 |
| 2025-08-08 | Chan Phillip P. Chief Executive Officer | Grant or award | +105,600 | 1,382,963 | ||
| 2025-08-08 | Chan Phillip P. Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +136,400 | 136,400 | ||
| 2025-02-24 | Chan Phillip P. Chief Executive Officer | Other acquisition | +34,168 | $1.13 | $39K | 1,277,363 |
| 2025-02-24 | Chan Phillip P. Chief Executive Officer | Other disposition · Series A Right Warrants (right to buy) | −34,168 | $1.13 | $39K | 0 |
| 2025-01-17 | Chan Phillip P. Chief Executive Officer | Option exercise | +90,832 | $1.00 | $91K | 1,243,195 |
| 2025-01-17 | Chan Phillip P. Chief Executive Officer | Option exercise · Subscription Rights (right to buy) | −90,832 | 0 | ||
| 2025-01-17 | Chan Phillip P. Chief Executive Officer | Other acquisition · Series A Right Warrants | +90,832 | 90,832 | ||
| 2025-01-17 | Chan Phillip P. Chief Executive Officer | Other acquisition · Series B Right Warrants | +90,832 | 90,832 | ||
| 2024-04-02 | Chan Phillip P. Chief Executive Officer | Grant or award | +96,000 | 1,164,704 | ||
| 2024-04-02 | Chan Phillip P. Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +124,000 | 124,000 | ||
| 2024-03-29 | Chan Phillip P. Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +129,998 | 129,998 | ||
| 2023-12-13 | Chan Phillip P. Chief Executive Officer | Purchase | +75,188 | $1.33 | $100K | 1,068,704 |
| 2023-12-13 | Chan Phillip P. Chief Executive Officer | Purchase · Common Stock Warrant (Right to Buy) | +26,315 | 26,315 | ||
| 2023-07-07 | Chan Phillip P. Chief Executive Officer | Grant or award | +87,000 | 1,006,548 | ||
| 2023-07-07 | Chan Phillip P. Chief Executive Officer | Grant or award · Stock Option (right to buy) | −112,000 | 112,000 |
Page 1 of 6 · 107 trades